Skip to main content
SpringerLink
Log in

The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

P21-activated kinase 5 (PAK5) is the recently identified member of the group II p21-activated kinases (PAKs) family, which is characterized by a highly conserved amino-terminal Cdc42/Rac interactive binding domain and a carboxyl terminal kinase domain. However, the role of PAK5 in gynecological cancers has not been evaluated so far. It is remarkable that we found PAK5 was overexpressed in epithelial ovarian cancer (EOC), which is faced with an obstacle of paclitaxel resistance. Therefore, in this study, we aim to examine the PAK5 expression during EOC progression, the role of PAK5 in malignant progression of EOC and the probable relationship between PAK5 and EOC paclitaxel resistance. By immunohistochemistry, our results showed that PAK5 expression was increased with EOC progression through the adenoma to carcinoma sequence, with the highest expression level in invasive and metastatic EOCs. Furthermore, the expression level of PAK5 was also found to increase in accordance with the development of EOC Federation International of Gynecology and Obstetrics stages (P = 0.038) and differentiation grades (P = 0.008). Remarkably, those patients who recurred within 6 months after accepting tumor reductive surgery and the following carboplatin + paclitaxel chemotherapy had the highest PAK5 expression (P = 0.015). Moreover, in in vitro studies, we found that SK-OV-3 cell growth was decreased while paclitaxel chemosensitivity was correspondingly increased with the down-regulation of PAK5. Taken together, our study demonstrated that PAK5 is correlated to human EOC and increased PAK5 expression promotes EOC progression, and PAK5 regulates EOC cell paclitaxel chemoresistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cotteret S, Jaffer ZM, Beeser A, Chernoff J (2003) p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 23(16):5526–5539

    Article  PubMed  CAS  Google Scholar 

  2. Wang X, Gong W, Qing H, Geng Y, Wang X, Zhang Y et al (2010) p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol 31(6):575–582

    Article  PubMed  CAS  Google Scholar 

  3. Cau J, Faure S, Comps M, Delsert C, Morin N (2001) A novel p21-activated kinase binds the actin and microtubule networks and induces microtubule stabilization. J Cell Biol 155(6):1029–1042

    Article  PubMed  CAS  Google Scholar 

  4. Nguyen TV, Galvan V, Huang W, Banwait S, Tang H, Zhang J et al (2008) Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem 104(4):1065–1080

    Article  PubMed  CAS  Google Scholar 

  5. Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O et al (2007) Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15(2):201–213

    Article  PubMed  CAS  Google Scholar 

  6. Dan I, Watanabe NM, Kusumi A (2001) The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 11(5):220–230

    Article  PubMed  CAS  Google Scholar 

  7. Cotteret S, Chernoff J (2006) Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol Cell Biol 26(8):3215–3230

    Article  PubMed  CAS  Google Scholar 

  8. Dan C, Nath N, Liberto M, Minden A (2002) PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol 22(2):567–577

    Article  PubMed  CAS  Google Scholar 

  9. Salminen A, Suuronen T, Kaarniranta K (2008) ROCK, PAK, and Toll of synapses in Alzheimer’s disease. Biochem Biophys Res Commun 371(4):587–590

    Article  PubMed  CAS  Google Scholar 

  10. Timm T, Matenia D, Li XY, Griesshaber B, Mandelkow EM (2006) Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis 3(4–5):207–217

    Article  PubMed  CAS  Google Scholar 

  11. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413–437

    Article  PubMed  Google Scholar 

  12. Vasey PA (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89(Suppl 3):S23–S28

    Article  PubMed  CAS  Google Scholar 

  13. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327

    Article  PubMed  CAS  Google Scholar 

  14. Detre S, Saclani Jotti G, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876–878

    Article  PubMed  CAS  Google Scholar 

  15. Lopez-Gasco P, Iglesias I, Benedi J, Lozano R, Blanco MD (2012) Characterization and in vitro bioactivity evaluation of paclitaxel-loaded polyester nanoparticles. Anticancer Drugs 23(9):947–958

    PubMed  CAS  Google Scholar 

  16. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK et al (2004) p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279(2):1422–1428

    Article  PubMed  CAS  Google Scholar 

  17. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98(10):671–680

    Article  PubMed  CAS  Google Scholar 

  18. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO et al (2004) Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 10(10):3448–3456

    Article  PubMed  CAS  Google Scholar 

  19. Wells CM, Abo A, Ridley AJ (2002) PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci 115(Pt 20):3947–3956

    Article  PubMed  CAS  Google Scholar 

  20. Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J et al (2005) PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell 16(9):4410–4422

    Article  PubMed  CAS  Google Scholar 

  21. Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E et al (2002) Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene 21(24):3939–3948

    Article  PubMed  CAS  Google Scholar 

  22. Giroux V, Iovanna JL, Garcia S, Dagorn JC (2009) Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Ther 16(9):731–740

    Article  PubMed  CAS  Google Scholar 

  23. Brigulova K, Cervinka M, Tosner J, Sedlakova I (2010) Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro 24(8):2108–2115

    Article  PubMed  CAS  Google Scholar 

  24. Salom E, Penalver M, Homesley H, Burrell M, Garrett A, Presant CA et al (2012) Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. J Transl Med 10(1):162

    Article  PubMed  CAS  Google Scholar 

  25. Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA (2008) p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem 105(1):167–175

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr YinBin Liu (Department of Surgery, Xinhua Hospital, Shanghai, China) and XinYuan Lao (Hollybio, Shanghai, China) for technical assistance.

Author information

Authors and Affiliations

  1. Department of Gynecology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People’s Republic of China

    Diyou Li & Ping Zhang

  2. Department of Pathology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People’s Republic of China

    Xiaohong Yao

Authors
  1. Diyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, D., Yao, X. & Zhang, P. The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer. Mol Cell Biochem 383, 191–199 (2013). https://doi.org/10.1007/s11010-013-1767-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-013-1767-7

Keywords

Search

Navigation